Agenda-setting intelligence, analysis and advice for the global fashion community.
Eli Lilly forecast 2026 profit above Wall Street estimates on Wednesday, betting on surging demand for its obesity drugs as the world’s most valuable drugmaker prepares to launch its oral weight-loss pill later this year.
Please sign in to ensure you can read our agenda-setting intelligence, analysis and advice. Or get in touch at support@businessoffashion.com if you experience difficulties.




